Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction
- PMID: 19558195
- DOI: 10.1007/BF03256142
Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction
Abstract
Background: Prescription opioid (RxO) abuse, dependence and misuse is a significant and growing problem in the US, and is associated with a substantial economic burden. Such abuse may be reduced by theoretical formulations that minimize the possibility of abuse, dependence and misuse of RxOs by injection, snorting, crushing or chewing. As well as public health and safety benefits, use of an abuse-deterrent/resistant RxO (ADO) that may deter abuse, dependence and misuse could also generate cost savings.
Objectives: To estimate potential annual cost savings to US third-party payers realized from introducing a theoretical ADO.
Methods: A budget-impact model (BIM) was developed to assess potential cost savings from the introduction of an ADO to third-party payers. The BIM included information on ADO attributes, costs associated with RxO abuse-related episodes, prevalence of RxO abuse and potential market share capture of the new ADO. Numbers of abuse-related episodes were calculated using a database on admissions to substance abuse treatment centres and other national surveys. Direct (medical and pharmaceutical) costs associated with RxO abuse, dependence and misuse were calculated using de-identified employer claims data (n > 6 000 000) for costs of abuse-related episodes. All cost estimates are in $US, year 2006 values. The BIM was developed for a theoretical prescription drug with therapeutic properties similar to those of controlled-release oxycodone, in a formulation that is specifically designed to resist or deter common methods of abuse, including injection, crushing, snorting and chewing.
Results: Potential cost savings to third-party payers from introducing an ADO for the US (assuming a privately insured cost structure) could range from approximately $US0.6 billion to $US1.6 billion per year depending on different possible scenarios.
Conclusion: While savings estimates from introduction of an ADO depend on a range of assumptions, cost savings would be substantial.
Similar articles
-
Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective.Clin J Pain. 2006 Oct;22(8):667-76. doi: 10.1097/01.ajp.0000210915.80417.cf. Clin J Pain. 2006. PMID: 16988561
-
Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.J Med Econ. 2014 Apr;17(4):279-87. doi: 10.3111/13696998.2014.897628. Epub 2014 Mar 7. J Med Econ. 2014. PMID: 24559196
-
Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.J Opioid Manag. 2017 Sep/Oct;13(5):291-301. doi: 10.5055/jom.2017.0398. J Opioid Manag. 2017. PMID: 29199395
-
Economic burden of prescription opioid misuse and abuse.J Manag Care Pharm. 2009 Sep;15(7):556-62. doi: 10.18553/jmcp.2009.15.7.556. J Manag Care Pharm. 2009. PMID: 19739878 Free PMC article. Review.
-
Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?Drugs. 2012 Sep 10;72(13):1713-23. doi: 10.2165/11635860-000000000-00000. Drugs. 2012. PMID: 22931520 Review.
Cited by
-
Prescription opioid abuse: challenges and opportunities for payers.Am J Manag Care. 2013 Apr;19(4):295-302. Am J Manag Care. 2013. PMID: 23725361 Free PMC article.
-
Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization.Am Health Drug Benefits. 2020 Feb;13(1):21-31. Am Health Drug Benefits. 2020. PMID: 32165996 Free PMC article.
-
Opioid Analgesics in Georgia Medicaid: Trends in Potential Inappropriate Prescribing Practices by Demographic Characteristics, 2009-2014.J Manag Care Spec Pharm. 2018 Sep;24(9):886-894. doi: 10.18553/jmcp.2018.24.9.886. J Manag Care Spec Pharm. 2018. PMID: 30156455 Free PMC article.
-
Opioids in Georgia Medicaid: Gender and Insurance Disparities in Utilization and Potential Inappropriate Prescribing Practices.J Pharm Health Serv Res. 2018 Jun;9(2):101-108. doi: 10.1111/jphs.12215. Epub 2018 Jan 16. J Pharm Health Serv Res. 2018. PMID: 30034551 Free PMC article.
-
Characteristics of High-Cost Patients Diagnosed with Opioid Abuse.J Manag Care Spec Pharm. 2015 Oct;21(10):902-12. doi: 10.18553/jmcp.2015.21.10.902. J Manag Care Spec Pharm. 2015. PMID: 26402390 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials